X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES CIPLA JUBILANT LIFE SCIENCES/
CIPLA
 
P/E (TTM) x 26.0 44.3 58.6% View Chart
P/BV x 5.3 3.9 137.9% View Chart
Dividend Yield % 0.3 0.3 102.7%  

Financials

 JUBILANT LIFE SCIENCES   CIPLA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
CIPLA
Mar-17
JUBILANT LIFE SCIENCES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs187622 30.0%   
Low Rs65458 14.2%   
Sales per share (Unadj.) Rs364.3181.9 200.4%  
Earnings per share (Unadj.) Rs6.812.9 53.2%  
Cash flow per share (Unadj.) Rs24.529.3 83.6%  
Dividends per share (Unadj.) Rs3.002.00 150.0%  
Dividend yield (eoy) %2.40.4 643.2%  
Book value per share (Unadj.) Rs164.9155.7 105.9%  
Shares outstanding (eoy) m159.28804.51 19.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 11.6%   
Avg P/E ratio x18.442.0 43.8%  
P/CF ratio (eoy) x5.118.4 27.9%  
Price / Book Value ratio x0.83.5 22.0%  
Dividend payout %43.815.5 282.0%   
Avg Mkt Cap Rs m20,061434,516 4.6%   
No. of employees `0006.223.0 26.8%   
Total wages/salary Rs m11,05226,338 42.0%   
Avg. sales/employee Rs Th9,383.06,349.1 147.8%   
Avg. wages/employee Rs Th1,786.91,143.0 156.3%   
Avg. net profit/employee Rs Th176.3449.3 39.2%   
INCOME DATA
Net Sales Rs m58,034146,302 39.7%  
Other income Rs m1912,287 8.3%   
Total revenues Rs m58,224148,589 39.2%   
Gross profit Rs m5,78624,758 23.4%  
Depreciation Rs m2,81213,229 21.3%   
Interest Rs m3,2371,594 203.1%   
Profit before tax Rs m-7212,222 -0.6%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m6961,798 38.7%   
Profit after tax Rs m1,09010,354 10.5%  
Gross profit margin %10.016.9 58.9%  
Effective tax rate %-965.914.7 -6,566.9%   
Net profit margin %1.97.1 26.5%  
BALANCE SHEET DATA
Current assets Rs m29,28087,370 33.5%   
Current liabilities Rs m38,91233,081 117.6%   
Net working cap to sales %-16.637.1 -44.7%  
Current ratio x0.82.6 28.5%  
Inventory Days Days8487 97.0%  
Debtors Days Days5162 81.3%  
Net fixed assets Rs m55,712111,567 49.9%   
Share capital Rs m1551,609 9.6%   
"Free" reserves Rs m20,968123,645 17.0%   
Net worth Rs m26,265125,254 21.0%   
Long term debt Rs m17,16936,454 47.1%   
Total assets Rs m88,606209,532 42.3%  
Interest coverage x1.08.7 11.3%   
Debt to equity ratio x0.70.3 224.6%  
Sales to assets ratio x0.70.7 93.8%   
Return on assets %4.95.7 85.7%  
Return on equity %4.28.3 50.2%  
Return on capital %11.68.5 136.1%  
Exports to sales %37.834.2 110.5%   
Imports to sales %16.58.3 197.7%   
Exports (fob) Rs m21,93350,050 43.8%   
Imports (cif) Rs m9,56712,203 78.4%   
Fx inflow Rs m22,00451,066 43.1%   
Fx outflow Rs m11,74917,678 66.5%   
Net fx Rs m10,25533,388 30.7%   
CASH FLOW
From Operations Rs m8,02623,824 33.7%  
From Investments Rs m-1,744-13,127 13.3%  
From Financial Activity Rs m-4,447-13,239 33.6%  
Net Cashflow Rs m1,834-2,478 -74.0%  

Share Holding

Indian Promoters % 45.6 16.0 285.0%  
Foreign collaborators % 3.5 20.8 16.8%  
Indian inst/Mut Fund % 8.7 12.2 71.3%  
FIIs % 21.2 23.7 89.5%  
ADR/GDR % 0.0 1.1 -  
Free float % 21.1 26.2 80.5%  
Shareholders   23,815 161,166 14.8%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   SUVEN LIFE  SUN PHARMA  PFIZER  TTK HEALTHCARE  SHASUN PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Impacted by one offs (Quarterly Results Update - Detailed)

Jun 2, 2016

Cipla has announced its 4QFY16 results. The company has reported 7.6% YoY growth in sales and a decline of 68.9% YoY in net profits. Here is our analysis of the results.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Jan 19, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - TTK HEALTHCARE COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS